Min Min Yang
Chief Executive Officer at PHARMABLOCK SCIENCES (NANJING), INC.
Net worth: 192 M $ as of 29/04/2024
Profile
Founder of PharmaBlock Sciences (Nanjing), Inc., Min Min Yang is Chairman at this company. He is also on the board of Shanghai Ark Biopharmaceutical Co., Ltd.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
02/07/2023 | 30,980,300 ( 99.23% ) | 144 M $ | 29/04/2024 | |
02/07/2023 | 10,326,800 ( 6.13% ) | 48 M $ | 29/04/2024 |
Min Min Yang active positions
Companies | Position | Start |
---|---|---|
PHARMABLOCK SCIENCES (NANJING), INC. | Chief Executive Officer | 20/04/2023 |
GEMPHARMATECH CO., LTD. | Director/Board Member | 18/10/2023 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Director/Board Member | 28/02/2021 |
Training of Min Min Yang
Nanjing University | Graduate Degree |
Auburn University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
GEMPHARMATECH CO., LTD. | Health Technology |
Private companies | 1 |
---|---|
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Health Technology |
- Stock Market
- Insiders
- Min Min Yang